European Commission Strongly Recommends the Use of Generic and Biosimilar Medicines to Ensure the Sustainability of Healthcare Systems

14 October 2016

Medicines for Europe welcomes the publication of the ‘Joint Report […]

Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market

19 September 2016

Biosimilar medicines provide a tremendous opportunity for governments throughout Europe […]

Industry Welcomes the European Commission Workshop on the Uptake of Biosimilar Medicines

20 June 2016

The European pharmaceutical industry welcomes the workshop organised today by […]

European Health Ministers Call for More Competition in Pharmaceutical Markets

17 June 2016

Medicines for Europe will engage rapidly with Health Ministers across […]

IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly

15 June 2016

Biosimilar Medicines for Rheumatologists: Bridging the Gap between Regulatory Science and Medical Societies

10 June 2016

Over the past decade, biosimilar medicines have generated more than […]

Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda

9 June 2016

During the next two days, the key pharmaceutical industry leaders […]

Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation / 10th June 2016, 08:15–09:45 Capital Suite 09, ExCel London

17 May 2016

10 Years of Biosimilar Medicines: Transforming Healthcare

28 April 2016

Biosimilar medicines provide an opportunity to increase patient access to […]

6 out of 10 Doctors Have Already Prescribed Biosimilar Medicines, According to EuropaBio Paper

20 April 2016

Medicines for Europe and its Biosimilar Medicines Group took note […]